AntriaBio seeks FDA nod for trial of once-weekly insulin

AntriaBio (OTC:ANTB) said today that it filed an investigational new drug application with the FDA for its once-weekly basal insulin.

If the Louisville, Colo.-based company wins approval from the FDA, it plans to launch a Phase I clinical trial of AB101 in patients with Type I diabetes.

Get the full story at our sister site, Drug Delivery Business News.

The post AntriaBio seeks FDA nod for trial of once-weekly insulin appeared first on MassDevice.

from MassDevice http://ift.tt/2svSsZo